Imagnostix: a simple blood-based test to flag Alzheimer’s risk
Official title: Development of "Imagnostix": A Liquid Biopsy System for Alzheimer's Disease
Funded at 5m Biomed, LLC · NIH-11417991 · Data updated 2026-11-12
A new blood-based test called Imagnostix aims to help identify people who may be developing Alzheimer’s disease earlier and more cheaply than current methods.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | 5m Biomed, LLC NIH-funded |
| Lab location | 1 site (Johns Creek, United States) |
| Project start | August 15, 2022 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $811,413 |
| NIH project number | 5R42AG078718-03 |
| Project ID | NIH-11417991 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults at risk for Alzheimer’s disease or with early cognitive concerns who may benefit from earlier diagnosis and monitoring.
✕Less likely to help
Individuals without risk factors or early signs of AD unlikely to benefit from this specific biomarker-focused test.
What this research studies
This project focuses on creating a liquid biopsy approach to detect Alzheimer’s disease biomarkers, aiming to identify the disease before symptoms appear. It will explore how a blood test could reflect brain changes linked to AD and related dementias. If successful, the test could enable earlier diagnosis, more timely interventions, and monitoring of disease progression in patients and at-risk individuals.
Why it matters
Potential benefit: If successful, this test could allow earlier detection and more targeted management of Alzheimer’s disease.
How similar studies have gone: Biomarker-based blood tests for neurodegenerative diseases have shown promise in early studies, but require further validation.
Where this research is happening
-
5m Biomed, LLC
Johns Creek, United States Active
Researchers
- Principal investigator: Li, Yuancheng — 5m Biomed, LLC
- Study coordinator: Li, Yuancheng
Related research
Other NIH-funded projects on the same topics.
-
Imagnostix — a blood test to detect Alzheimer's early
Imagnostix is a new blood test that looks for Alzheimer's-related proteins to find early brain changes in people with memory concerns or at risk for Alzheimer's.
-
A new method for early detection of Alzheimer's disease using blood samples
This study is working on a new, easy way to check for signs of Alzheimer's disease in blood samples, which could help doctors catch it earlier and more affordably, making it easier for more people to get tested.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.